应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06996 德琪医药-B
已收盘 09-25 16:08:14
3.470
-0.005
-0.14%
最高
3.575
最低
3.340
成交量
50.55万
今开
3.475
昨收
3.475
日振幅
6.76%
总市值
23.84亿
流通市值
23.84亿
总股本
6.87亿
成交额
172.67万
换手率
0.07%
流通股本
6.87亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
德琪医药-B：9月25日回购14.7万股股份，涉资约50.49万港元
公告速递 · 57分钟前
德琪医药-B：9月25日回购14.7万股股份，涉资约50.49万港元
德琪医药-B(06996)9月25日斥资50.49万港元回购14.7万股
智通财经 · 18:06
德琪医药-B(06996)9月25日斥资50.49万港元回购14.7万股
德琪医药-B 9月24日回购11.75万股，耗资约40.50万港元
公告速递 · 09-24 17:42
德琪医药-B 9月24日回购11.75万股，耗资约40.50万港元
德琪医药-B(06996)9月24日斥资40.5万港元回购11.75万股
智通财经 · 09-24 17:41
德琪医药-B(06996)9月24日斥资40.5万港元回购11.75万股
德琪医药-B9月23日回购1,500股股份 耗资5,340港元
公告速递 · 09-23 18:20
德琪医药-B9月23日回购1,500股股份 耗资5,340港元
德琪医药-B(06996.HK)9月23日斥资5340港元回购1500股
智通财经 · 09-23 18:01
德琪医药-B(06996.HK)9月23日斥资5340港元回购1500股
创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%
老虎资讯综合 · 09-23 11:01
创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%
德琪医药-B：9月22日回购26,500股，耗资约9.32万港元
公告速递 · 09-22
德琪医药-B：9月22日回购26,500股，耗资约9.32万港元
德琪医药-B回购5,000股股份，总涉资17,200港元
公告速递 · 09-21
德琪医药-B回购5,000股股份，总涉资17,200港元
德琪医药-B(06996.HK)9月21日斥资1.72万港元回购5000股
智通财经 · 09-21
德琪医药-B(06996.HK)9月21日斥资1.72万港元回购5000股
港股异动 | 德琪医药-B(06996)涨超9% ATG-022关键性III期CLINCH-3研究完成首例患者给药
智通财经 · 09-21
港股异动 | 德琪医药-B(06996)涨超9% ATG-022关键性III期CLINCH-3研究完成首例患者给药
德琪医药-B：TCT (BVI) Limited增持，好仓比例升至10.84%
港股披露 · 09-17
德琪医药-B：TCT (BVI) Limited增持，好仓比例升至10.84%
德琪医药-B：唐晟增持，好仓比例升至0.07%
港股披露 · 09-16
德琪医药-B：唐晟增持，好仓比例升至0.07%
德琪医药-B：钱晶增持，好仓比例升至0.07%
港股披露 · 09-16
德琪医药-B：钱晶增持，好仓比例升至0.07%
交银国际：维持德琪医药(06996.HK)“买入”评级 目标价10港元
智通财经 · 09-15
交银国际：维持德琪医药(06996.HK)“买入”评级 目标价10港元
【券商聚焦】交银国际维持德琪医药（06996）买入评级 指TCE平台差异化持续加深
金吾财讯 · 09-15
【券商聚焦】交银国际维持德琪医药（06996）买入评级 指TCE平台差异化持续加深
德琪医药-B(06996.HK)因受限制股份单位获归属而发行合共1009万股
智通财经 · 09-14
德琪医药-B(06996.HK)因受限制股份单位获归属而发行合共1009万股
德琪医药-B：9月14日增发1009万股，已发行股本变动
公告速递 · 09-14
德琪医药-B：9月14日增发1009万股，已发行股本变动
德琪医药-B（06996）拟于2026年9月10日授出1,152万份受限制股份单位
公告速递 · 09-10
德琪医药-B（06996）拟于2026年9月10日授出1,152万份受限制股份单位
德琪医药-B(06996.HK)授出1152万份受限制股份单位
智通财经 · 09-10
德琪医药-B(06996.HK)授出1152万份受限制股份单位
加载更多
公司概况
公司名称：
德琪医药-B
所属市场：
SEHK
上市日期：
--
主营业务：
德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。
发行价格：
--
{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":3.47,"timestamp":1790323694006,"preClose":3.475,"halted":0,"volume":505500,"delay":0,"changeRate":-0.0014388489208632786,"floatShares":687000000,"shares":687000000,"eps":-0.4433770491803279,"marketStatus":"已收盘","change":-0.005,"latestTime":"09-25 16:08:14","open":3.475,"high":3.575,"low":3.34,"amount":1726722,"amplitude":0.067626,"askPrice":3.485,"askSize":500,"bidPrice":3.47,"bidSize":24500,"shortable":3,"etf":0,"ttmEps":0.09812750845556514,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":5,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":3.475,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.441331,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"1118263749","title":"德琪医药-B：9月25日回购14.7万股股份，涉资约50.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118263749","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118263749?lang=zh_cn&edition=full","pubTime":"2026-09-25 18:11","pubTimestamp":1790331096,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年9月25日进行股份回购，合计回购147,000股普通股，占回购前公司已发行股本约0.0214%。回购价格区间介乎每股3.38港元至3.46港元，合计耗资约50.49万港元。公司本次回购的股份拟持作库藏股。回购完成后，公司已发行股份总数保持在689,536,632股，其中不含库藏股的已发行股份为687,210,132股，库藏股份为2,326,500股。公司表示，此次回购活动符合香港联合交易所有限公司的相关上市规则和适用法例的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B：9月25日回购14.7万股股份，涉资约50.49万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670444173","title":"德琪医药-B(06996)9月25日斥资50.49万港元回购14.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670444173","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670444173?lang=zh_cn&edition=full","pubTime":"2026-09-25 18:06","pubTimestamp":1790330781,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，于2026年9月25日，该公司斥资50.49万港元回购14.7万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","06996","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196937598","title":"德琪医药-B 9月24日回购11.75万股，耗资约40.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196937598","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196937598?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:42","pubTimestamp":1790242929,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年9月24日发布公告，披露当日在香港联交所场内回购117,500股普通股，占当日前已发行股本约0.0171%。回购价格介乎每股3.405港元至3.58港元，合计支付总金额约404,975.50港元。回购完成后，公司已发行股本变动为687,357,132股，库藏股增至2,179,500股，总股份数目保持为689,536,632股。截至本次回购后，已累计回购1,977,000股，占该回购授权通过日已发行股本约0.2911%。剩余可回购股份数量为65,947,413股。公司确认，本次回购已遵守香港联交所《主板上市规则》及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B 9月24日回购11.75万股，耗资约40.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469846","title":"德琪医药-B(06996)9月24日斥资40.5万港元回购11.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469846","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469846?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:41","pubTimestamp":1790242886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，于2026年9月24日，该公司斥资40.5万港元回购11.75万股股份，每股回购价3.405-3.58港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168890836","title":"德琪医药-B9月23日回购1,500股股份 耗资5,340港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168890836","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168890836?lang=zh_cn&edition=full","pubTime":"2026-09-23 18:20","pubTimestamp":1790158840,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年9月23日发布公告，披露在香港联合交易所场内回购1,500股普通股，占回购前公司已发行股份687,476,132股的约0.0002%。回购价为每股港币3.56元，合计支付港币5,340元。本次回购完成后，公司已发行股份总数仍为689,536,632股，其中已发行股份数量降至687,474,632股，库存股份增至2,062,000股。据公告披露，德琪医药-B此前于2026年6月10日获得股东大会通过股份购回授权，可购回最高数量共67,924,413股。公司确认，本次股份购回已遵守香港联交所的相关上市规则及适用法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B9月23日回购1,500股股份 耗资5,340港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669510246","title":"德琪医药-B(06996.HK)9月23日斥资5340港元回购1500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669510246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669510246?lang=zh_cn&edition=full","pubTime":"2026-09-23 18:01","pubTimestamp":1790157666,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06996","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","03347","02359","03759","06622","06978","06996","00241","09606","09688","09966","06606","09995","02137","06618","02268","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124686374","title":"德琪医药-B：9月22日回购26,500股，耗资约9.32万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124686374","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124686374?lang=zh_cn&edition=full","pubTime":"2026-09-22 18:06","pubTimestamp":1790071600,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年9月22日发布公告，披露当日于香港联交所场内回购股份26,500股，约占回购前公司已发行股本的0.0039%。本次回购每股价格介于3.51港元至3.52港元，合计耗资93,224.35港元。回购完成后，公司已发行股份总数仍为689,536,632股，不包括库藏股的已发行股份减少至687,476,132股，库藏股数量增至2,060,500股。公司已于2026年6月10日获得回购授权，授权购回股份总数为67,924,413股，截至目前已回购1,858,000股，约占授权通过当日已发行股本的0.2735%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B：9月22日回购26,500股，耗资约9.32万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186517212","title":"德琪医药-B回购5,000股股份，总涉资17,200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186517212","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186517212?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:06","pubTimestamp":1789988785,"startTime":"0","endTime":"0","summary":"德琪医药-B2026年9月21日发布公告，披露已于当日于香港联交所场内回购公司股份5,000股，占该次回购前公司已发行股本约0.0007%。本次回购的每股价格在港币3.31港元至3.48港元之间，平均回购价约3.44港元，合计动用资金17,200港元。回购完成后，公司已发行股份总数为687,502,632股，库藏股数量增至2,034,000股，总股本合计689,536,632股。公司于2026年6月10日通过股份购回授权，最多回购67,924,413股；截至公告发布当日，公司已合计回购1,831,500股，占授权分配股份总数的0.2696%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购5,000股股份，总涉资17,200港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150164","title":"德琪医药-B(06996.HK)9月21日斥资1.72万港元回购5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669150164?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:02","pubTimestamp":1789988571,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","06996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669153521","title":"港股异动 | 德琪医药-B(06996)涨超9% ATG-022关键性III期CLINCH-3研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2669153521","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669153521?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:11","pubTimestamp":1789974710,"startTime":"0","endTime":"0","summary":"消息面上，9月21日，据德琪医药官微消息，公司今日宣布，靶向CLDN18.2的抗体偶联药物ATG-022用于治疗CLDN18.2阳性晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究在中国完成首例患者给药。该研究目前于中国率先启动并完成首例患者给药，公司计划将其拓展为多区域临床试验，旨在为ATG-022单药治疗CLDN18.2阳性晚期胃或胃食管结合部腺癌提供坚实的临床依据，以支持其未来的上市批准申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1583","BK1574","BK4588","VXUS","BK4585","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125322665","title":"德琪医药-B：TCT (BVI) Limited增持，好仓比例升至10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125322665","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125322665?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:24","pubTimestamp":1789637042,"startTime":"0","endTime":"0","summary":"TCT (BVI) Limited于2026年9月14日通过其全资子公司Antengene Resurrection Limited获配发及发行新股份，从而增持德琪医药-B股份。该笔交易属场外配售，未经联交所公开市场撮合，不属二级市场直接买卖。TCT (BVI) Limited此次增持前持有德琪医药-B好仓6471.78万股，占比9.52%；增持后持股量为7480.78万股，好仓比例升至10.84%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115639718","title":"德琪医药-B：唐晟增持，好仓比例升至0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115639718","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115639718?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:33","pubTimestamp":1789551183,"startTime":"0","endTime":"0","summary":"唐晟于2026年9月10日通过场外股本衍生工具交易增持德琪医药-B股份，属场外衍生品交易，并非在二级市场直接买卖正股。唐晟此次增持前持有德琪医药-B好仓28.00万股，占比0.04%；增持后持股量为48.00万股，好仓比例升至0.07%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133874779","title":"德琪医药-B：钱晶增持，好仓比例升至0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133874779","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133874779?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:21","pubTimestamp":1789550470,"startTime":"0","endTime":"0","summary":"钱晶于2026年9月10日通过场外股本衍生工具交易增持德琪医药-B股份。该笔交易属场外衍生品交易，并非在二级市场直接买卖正股。钱晶此次增持前持有德琪医药-B好仓27.86万股，占比0.04%；增持后持股量为47.86万股，好仓比例升至0.07%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667170648","title":"交银国际：维持德琪医药(06996.HK)“买入”评级 目标价10港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667170648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667170648?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:55","pubTimestamp":1789462559,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","06996","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616906","title":"【券商聚焦】交银国际维持德琪医药（06996）买入评级 指TCE平台差异化持续加深","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616906","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667616906?lang=zh_cn&edition=full","pubTime":"2026-09-15 13:27","pubTimestamp":1789450027,"startTime":"0","endTime":"0","summary":"ATG-022将于10月的ESMO大会上公布II期CLINCH研究的最新结果。截至今年6月的数据显示，在后线GC患者中，1.8mg/kg剂量的ATG-022取得71%/67%的9个月/12个月OS率，mOS 在14个月中位随访时仍未达到。公司还计划于年底公布ATG-022 联合K药治疗1L/2L GC 的初步数据。该机构上调2026年收入预测以反映合作收入贡献、下调2027-28年预测以反映更谨慎的产品销售预期、同时上调ATG-022峰值销售预测35%至26亿元。该机构维持目标价10港元和买入评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991665","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668325","title":"德琪医药-B(06996.HK)因受限制股份单位获归属而发行合共1009万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668325","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667668325?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:07","pubTimestamp":1789384054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","06996","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110762610","title":"德琪医药-B：9月14日增发1009万股，已发行股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1110762610","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110762610?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:06","pubTimestamp":1789383996,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年9月14日在香港联交所刊发翌日披露报表，宣布因2022年受限制股份单位计划向董事及非董事授予股份奖励或期权并相应发行新股。本次共计增发1,240,000股及8,850,000股，发行价格均为每股0港元，分别占公司此次变动前已发行股份总数的约0.183%和1.3064%。增发完成后，德琪医药-B的已发行股份数量由677,417,632股增至687,507,632股，库藏股数额维持2,029,000股，合计股份总数为689,536,632股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"德琪医药-B：9月14日增发1009万股，已发行股本变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142183607","title":"德琪医药-B（06996）拟于2026年9月10日授出1,152万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1142183607","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142183607?lang=zh_cn&edition=full","pubTime":"2026-09-10 20:06","pubTimestamp":1789041963,"startTime":"0","endTime":"0","summary":"德琪医药-B9月10日公告称，其董事会已根据2022年受限制股份单位计划批准授出合计11,520,000份受限制股份单位，对应同等数量的公司普通股。此次授予不设购买价，授出当日公司股份收市价为每股3.45港元。公司称，RSU计划旨在肯定并激励合资格参与者，助力集团业务发展及人才保留。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666938635","title":"德琪医药-B(06996.HK)授出1152万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666938635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666938635?lang=zh_cn&edition=full","pubTime":"2026-09-10 20:04","pubTimestamp":1789041856,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06996","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":0.0692},{"period":"1month","weight":-0.1269},{"period":"3month","weight":0.053},{"period":"6month","weight":-0.2805},{"period":"1year","weight":-0.4637},{"period":"ytd","weight":-0.0831}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0922},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0663},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034689},{"month":5,"riseRate":0.5,"avgChangeRate":0.014763},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.127204},{"month":7,"riseRate":0.333333,"avgChangeRate":0.018605},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.036567},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.026097},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}